Filtered By:
Specialty: Neurology
Drug: Coumadin
Education: Study

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 277 results found since Jan 2013.

Clinical, lifestyle, socioeconomic determinants and rate of asymptomatic intracranial atherosclerosis in stroke free Pakistanis
Conclusion: ICAD was found on MRI in one in three asymptomatic Pakistanis and was associated with modifiable risks. Initiatives targeting primary prevention may be able to decrease the burden of disease caused by stroke due to ICAD.Study Registration NumberNCT02072876 2/25/2014
Source: BMC Neurology - August 15, 2014 Category: Neurology Authors: Ayeesha KamalFarzin MajeedOmrana PashaHasan RehmanMuhammad IslamIqbal AzamMuhammad IlyasMunawar HussainKamran MasoodBilal AhmedSumaira NazirZafar SajjadScott Kasner Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

Rivaroxaban and Apixaban Reduce Hemorrhagic Transformation After Thrombolysis by Protection of Neurovascular Unit in Rat Basic Sciences
Conclusions— This study shows a lower risk of intracerebral hemorrhage after tissue-type plasminogen activator treatment in rats with ischemic stroke that are pretreated with rivaroxaban and apixaban compared with pretreatment with warfarin. Reducing neurovascular dissociation by rivaroxaban and apixaban compared with warfarin could partly explain a reduction in hemorrhagic complications reported in clinical studies.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Kono, S., Yamashita, T., Deguchi, K., Omote, Y., Yunoki, T., Sato, K., Kurata, T., Hishikawa, N., Abe, K. Tags: Animal models of human disease Basic Sciences Source Type: research

New aspects of stroke medicine.
Abstract Systemic thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) remains the only effective and approved medical treatment of acute ischemic stroke. Several studies have demonstrated the importance of rapid recanalization. The efficacy of thrombectomy has so far not been sufficiently shown in randomized clinical trials; therefore, inclusion of suitable patients in one of the currently ongoing randomized trials is of great importance. The early treatment with magnesium after acute ischemic stroke during the pre-hospital phase did not prove to be neuroprotective. Intermittent pneumatic compr...
Source: Der Nervenarzt - June 28, 2014 Category: Neurology Authors: Diener HC, Frank B, Hajjar K, Weimar C Tags: Nervenarzt Source Type: research

Warfarin-Associated Intracerebral Hemorrhage After Ischemic Stroke Brief Reports
Conclusions— In this nationwide study, the risk of warfarin-associated ICH among ischemic stroke patients was low and did not change during the 2000s.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Asberg, S., Eriksson, M., Henriksson, K. M., Terent, A. Tags: Intracerebral Hemorrhage, Anticoagulants, Epidemiology Brief Reports Source Type: research

Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 — Implications for warfarin management and outcome in Croatian patients with acute stroke
Conclusion: Our data indicated rapid and safe anticoagulation achieved by using pharmacogenetically-predicted warfarin dose in high-risk acute stroke patients without increasing the risk of warfarin dosage complications in an elderly population.Highlights:
Source: Journal of the Neurological Sciences - May 6, 2014 Category: Neurology Authors: Svjetlana Šupe, Nada Božina, Vesna Matijević, Antonela Bazina, Antonija Mišmaš, Josip Ljevak, Domagoj Alvir, Mario Habek, Zdravka Poljaković Tags: Original Articles Source Type: research

Warfarin Versus Aspirin for Prevention of Cognitive Decline in Atrial Fibrillation: Randomized Controlled Trial (Birmingham Atrial Fibrillation Treatment of the Aged Study) Clinical Sciences
Conclusions— We found no evidence that anticoagulation confers clinically important protection over aspirin against cognitive decline as measured by the Mini-Mental State Examination in atrial fibrillation in the first 33 months of treatment other than that provided by preventing clinical stroke. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN89345269.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Mavaddat, N., Roalfe, A., Fletcher, K., Lip, G. Y. H., Hobbs, F. D. R., Fitzmaurice, D., Mant, J. Tags: Arrhythmias, clinical electrophysiology, drugs, Primary and Secondary Stroke Prevention, Anticoagulants Clinical Sciences Source Type: research

90 Day Outcomes in Stroke/Transient Ischemic Attack Patients Receiving Initial or Follow-up Care in a Comprehensive Outpatient Stroke Center (P3.120)
CONCLUSIONS: The completion of diagnostic evaluation and implementation or adjustment of treatments including optimizing antiplatelet therapy or changing to coumadin when cardiac monitoring demonstrates atrial fibrillation in a timely manner has resulted in better than expected outcomes. We feel this is due to "closing the loop" in the episode of care.Disclosure: Dr. Bates has nothing to disclose. Dr. Westphal has nothing to disclose. Dr. Rainka has nothing to disclose. Dr. Gengo has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bates, V., Westphal, E., Rainka, M., Gengo, F. Tags: Cerebrovascular Disease and Interventional Neurology: Primary and Comprehensive Stroke Centers Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (P5.003)
CONCLUSIONS: This imputed placebo analysis suggests that apixaban significantly reduces all-cause mortality by about one-third in patients with AF.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance in formatting the abstract to ensure compliance with AAN guidelines was provided by Stephanie Finucane of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. McMurray has nothing to disclose. Dr. Hart has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals Inc., and Bristol-Myers Squibb Co. Dr. Flaker has received personal c...
Source: Neurology - April 9, 2014 Category: Neurology Authors: McMurray, J., Hart, R., Flaker, G., Lopes, R., Wang, J., Hanna, M., Alexander, J., Granger, C., Wallentin, L. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research

Strategy to a 5 Minute Door to Needle Time (S5.005)
CONCLUSIONS:Our experience suggests that the "Target: Stroke" strategies (EMS initiation of stroke codes, rapid triage, rt-PA before labs), SMART criteria, and three question tool to predict abnormal coagulation can significantly reduce the time to thrombolysis. However, a multi-disciplinary team, educated and dedicated to providing rapid ischemic stroke treatment, and the development of a culture in which faster treatment is a goal, is a factor that’s impact cannot be measured.Study Supported by:Disclosure: Dr. Parker has nothing to disclose. Dr. Swanson-Devlin has nothing to disclose. Dr. Jahnel has received person...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Parker, S., Swanson-Devlin, T., Jahnel, J., McNeil, C., Talkad, A., Beck, J., Nair, D., Wang, D. Tags: Cerebrovascular Disease and Interventional Neurology: Pre-hospital, Telemedicine, and Related Topics Source Type: research

Warfarin Associated Intracerebral Hemorrhage in Hong Kong Chinese (P7.142)
CONCLUSIONS: WICH is a serious complication of warfarin therapy with high mortality and morbidity. Initial ICH volume, presence of intraventricular hemorrhage and neurological deterioration are independent predictors of clinical outcome.Disclosure: Dr. Teo has nothing to disclose. Dr. Mahboobani has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Siu has nothing to disclose. Dr. Cheung has nothing to disclose. Dr. Ho has nothing to disclose. Dr. Lau has nothing to disclose. Dr. Chan has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Teo, K. C., Mahboobani, N. R., Lee, R., Siu, D. C., Cheung, R., Ho, S. L., Lau, G. K., Chan, K. H. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Outcome and Mortality Source Type: research

Dabigatran -The Future Of Cortical Venous Thrombosis Therapy -A Case Series Study (P6.025)
ConclusionsAs these cases demonstrate, Dabigatran appears be effective and safe in the treatment of single cortical venous sinus thrombosis . However large scale randomized controlled trials will be required to confirm its efficacy as a therapeutic modality .Disclosure: Dr. Mathew has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Sarma has nothing to disclose. Dr. Nadig has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mathew, T., Alexander, L., Sarma, G., Nadig, R. Tags: General Neurology VI Source Type: research

Direct Thrombin Inhibitors May Have A Decreased Risk Of Intracerebral Hemorrhage Compared With Older Anticoagulants (P5.140)
CONCLUSIONS: We found no significant difference in risk of ICH with DTI compared to the AC group and a trend towards lower risk with DTI. Future studies with larger numbers on DTIs are needed to confirm differences in ICH risk between DTIs and other anticoagulants.Disclosure: Dr. Ravipati has nothing to disclose. Dr. Woo has received research support from the National Institutes of Health. Dr. Sekar has received research support from the National Institutes of Health. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Flaherty has received personal compensation for activities with CSL Behr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ravipati, S., Woo, D., Sekar, P., Moomaw, C., Flaherty, M., Osborne, J. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage and Other Hemorrhages Source Type: research

Systemic Inflammation Exacerbates Stroke in Patients with Left Ventricular Assist Device (P4.235)
CONCLUSIONS:In LVAD patients, total prevention of cerebrovascular complications cannot be accomplished only by adjusting warfarin dosage to meet the therapeutic range. However, recognition of increased CRP and appropriate management of inflammation prior to the stroke onset may enable us to avoid its aggravation and secure patient’s opportunity for heart transplantation.Disclosure: Dr. Ohtomo has nothing to disclose. Dr. Iwata has received personal compensation for activities with Janssen Pharmaceuticals, Eisai Inc., Daiichi Pharmaceutical Corp., Ono Pharmaceutical, and Takeda Pharmaceutical Co. Ltd. Dr. Iwata has re...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ohtomo, R., Iwata, A., Kinoshita, O., Shimizu, J., Ono, M., Tsuji, S. Tags: Cerebrovascular Disease and Interventional Neurology: Cardiac Source Type: research